Kornimate/medical-research-clean huggingface dataset:
multi-center study on pediatric functional gastrointestinal disorders in mainland china

Conditions: Functional Gastrointestinal Disorders

Summary: this study plans to understand the prevalence and clinical characteristics of pediatric functional gastrointestinal disorders in mainland china through multi-center investigation and clinical epidemiological analysis, to reveal the prevalence characteristics and related factors of functional gastrointestinal disorders in children of all ages in mainland china, to establish a diagnostic standard system for pediatric functional gastrointestinal disorders in mainland china, to provide evidence-based basis for the formulation of new roman standard for functional gastrointestinal disorders, and to provide new ideas and treatment basis for the diagnosis and treatment of functional gastrointestinal disorders in children.

functional gastrointestinal disorders (fgids), also known as brain-intestinal interaction abnormalities, are associated with dynamic disorders, high visceral sensitivity, changes in mucosal and immune functions, changes in intestinal flora, and abnormal central nervous system regulatory functions. fgids are the most common causes of diagnosis and treatment of gastrointestinal diseases in children. during the past 10 years, new progress has been made in the study of various fgids in children of different ages. fgids rome commission of experts revised the relevant diagnostic criteria and officially published the rome iv criteria for pediatric fgids in gastroenterology in 2016. due to many factors, the epidemiological survey data of pediatric fgid are still lacking in china. whether rome ii, rome iii or rome iv, their diagnostic criteria and epidemiological data were from other countries and regions, so their suitability for china's children remains to be verified. this study plans to understand the prevalence and clinical characteristics of pediatric functional gastrointestinal disorders in mainland china through multi-center investigation and clinical epidemiological analysis, to reveal the prevalence characteristics and related factors of functional gastrointestinal disorders in children of all ages in mainland china, to establish a diagnostic standard system for pediatric functional gastrointestinal disorders in mainland china, to provide evidence-based basis for the formulation of new roman standard for functional gastrointestinal disorders, and to provide new ideas and treatment basis for the diagnosis and treatment of pediatric functional gastrointestinal disorders.

Eligibility criteria:
inclusion criteria: * children diagnosed with functional gastrointestinal disorders exclusion criteria: * children not diagnosed with functional gastrointestinal disorders

Keywords: functional gastrointestinal disorders children
sildenafil for chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive; Emphysema

Summary: the purpose of this study is to determine if sildenafil improves the exercise capacity and lung function of patients with chronic obstructive pulmonary disease.

patients with chronic obstructive pulmonary disease (copd) suffer from impaired exercise capacity and quality-of-life, largely related to shortness of breath. many of the therapies currently available for copd are aimed at improving these factors. exercise capacity is limited in part by high blood pressure in the blood vessels in the lungs. sildenafil, also known as viagra, is an fda-approved therapy for male erectile dysfunction. one of its effects is to relax (or open) the lung vessels, thereby lowering the blood pressure in the lungs. we hypothesize that sildenafil will result in an improvement in exercise capacity, quality-of-life, and shortness of breath. enrolled subjects will receive sildenafil or placebo for 4 weeks followed by exercise tests, breathing tests, and administration of quality-of-life questionnaires. subjects will then receive placebo or sildenafil (whichever one they did not receive for the first 4 weeks) for another 4 weeks, followed by the same testing.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic obstructive pulmonary disease (copd) or emphysema * fev1/fvc ratio \< 70% * fev1 \< 80% * stable medication regimen exclusion criteria: * copd exacerbation or hospitalization in the past 3 months * heart disease * contraindication to sildenafil * unrelated lung disease * inability to walk or pedal on a stationary bike * pregnancy or breast-feeding * pulmonary hypertension at rest

Keywords: chronic obstructive pulmonary disease emphysema phosphodiesterase inhibitors sildenafil exercise testing quality of life
value of multiple modalities using the spectra wavewriter spinal cord stimulator system

Conditions: Chronic Pain; Back Pain

Summary: to demonstrate the value of multiple modalities and sustained clinically significant pain relief in patients with chronic pain when using the boston scientific spectra wavewriter spinal cord stimulator (scs) system.


Eligibility criteria:
key inclusion criteria: * chronic pain of the trunk and/or limbs * 22 years of age or older at time of enrollment * willing and able to comply with all protocol-required procedures and assessments/evaluations provided in english * willing and capable of giving informed consent key exclusion criteria: * any pain-related diagnosis or medical/psychological condition that, in the clinician's best judgment, might confound reporting of study outcomes * significant cognitive impairment that, in the opinion of the investigator, would reasonably be expected to impair the study candidate's ability to participate in the study * current systemic infection, or local infection in close proximity to the anticipated surgical field * breast-feeding, pregnant or planning to get pregnant during the course of the study or not using adequate contraception * previous spinal cord stimulation trial or is already implanted with an active implantable device(s) (e.g. pacemaker, drug pump, implantable pulse generator) * participating, or intends to participate, in another clinical trial that may influence the data that will be collected for this study

Keywords: chronic pain back pain leg pain pain stimulation spinal cord stimulator implantable pulse generator
clinical outcomes following primary intracerebral hemorrhage

Conditions: Stroke; Intracerebral Hemorrhage

Summary: the investigators design an observational multi-center cohort study to provide contemporary information on the prevalence, characteristics, risk stratification，cost-effective ,treatments and prognosis of chinese hospitalized adult patients with primary intracerebral hemorrhage.

this cohort was an analysis based on patients from six stroke centers: the 2nd affiliated hospital of zhejiang university; the first people's hospital of pinghu, jiaxing; the first people's hospital of taizhou; the people's hospital of haiyan, jiaxing; tiantai county people's hospital, taizhou; the 2nd people's hospital of quzhou (please see more information of this cohort in supplement). all hospitals are located in zhejiang province. patients' data were entered by local trained registrars using standardised protocols, and the overall process of case registration, monitoring of the data quality, and inquiry and correction of erroneous data was managed and supervised by a steering committee. we included adult patients who (1) admitted for primary ich ; (2) underwent blood routine test (hemoglobin included) and ct scan as soon as they arrived at hospital; (3) were not treated with neurosurgical procedures. we excluded patients who (1) had ich secondary to known causes, including trauma, intracranial neoplasm and systemic diseases12, as well as anticoagulative agents; or had isolated intraventricular hemorrhage (ivh); (2) mrs \>2 before the current ich episode (according to past medical records or description from guardians. this study was approved by human research ethic committees at all participating centers, and conducted in compliance with the principles set forward by the declaration of helsinki.

Eligibility criteria:
inclusion criteria: - we included adult patients who (1) admitted for primary ich ; (2) underwent blood routine test (hemoglobin included) and ct scan as soon as they arrived at hospital; (3) were not treated with neurosurgical procedures. exclusion criteria: * we excluded patients who (1) had ich secondary to known causes, including trauma, intracranial neoplasm and systemic diseases12, as well as anticoagulative agents; or had isolated intraventricular hemorrhage (ivh); (2) mrs \>2 before the current ich episode (according to past medical records or description from guardians.

Keywords: primary intracerebral hemorrhage stroke outcomes
dapagliflozin in allo-hct for agvhd

Conditions: Graft-versus-host Disease (GVHD)

Summary: the goal of this clinical trial is to learn if dapagliflozin could prevent acute graft-versus-host disease (agvhd) in patients undergoing allogeneic hematopoietic cell transplantation (allo-hct) with haploidentical or unrelated donor and to assess its safety. the main questions it aims to answer are: dose dapagliflozin lower the cumulative incidence of agvhd? what medical problems do participants undergoing allo-hct from haploidentical or unrelated donor have when taking dapagliflozin? researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. participants will take dapagliflozin every day in -1 to 14 days.


Eligibility criteria:
inclusion criteria: * age 18 to 65 years old. * patients with hematologic malignancies indicated for allo-hct and having a suitable haploidentical or unrelated donor. * willing to undergo myeloablative conditioning and graft-versus-host disease prophylaxis base on cyclosporin a and methotrexate. * with eastern cooperative oncology group (ecog) performance status of 0-3. * patients with prior use of dapagliflozin or other hypoglycemic medications may switch to dapagliflozin, contingent upon the treating physician's assessment of contraindications, will be eligible. * signing an informed consent form, having the ability to comply with study and follow-up procedures. exclusion criteria: * with other malignancies. * with a previous history of autologous hematopoietic cell transplantation, allo-hct or chimeric antigen receptor t-cell therapy. * with a history of allergies to dapagliflozin. * with type 1 diabetes or a history of ketoacidosis. * with a history of recurrent urinary tract infections. * with severe organ dysfunction. * with active hepatitis b virus, hepatitis c virus, or human immunodeficiency virus infection. * in pregnancy or lactation period. * with any conditions not suitable for the trial (investigators' decision).

Keywords: dapagliflozin graft-versus-host disease allogeneic hematopoietic cell transplantation
efficacy of valproate in peripheral neuropathic pain

Conditions: Neuralgia; Neuropathic Peripheral Pain

Summary: the purpose of this study is to determine whether valproate is effective and well tolerated in the treatment of neuropathic peripheral pain. the drug is administered by intravenous route followed by oral route during 4 weeks.

background. neuropathic peripheral pain is often refractory to usual analgesics. some anticonvulsant drugs may be effective, but often partially only, and not always well tolerated. valproate is a well-known anticonvulsant drug, with moderate possible adverse events and for which an intravenous form is available. aim. the principal aim is to assess the efficacy and safety of sodium valproate in peripheral neuropathic pain. secondary aims are to asses the effect of iv and oral treatment on neurophysiologic measures. design. randomized, double-blind vs. placebo, parallel groups, monocentric clinical trial. treatments. experimental arm: intravenous eight-hour sodium valproate infusion, followed by a four-week oral route sodium valproate treatment. control arm: intravenous eight-hour placebo infusion, followed by a four-week oral route placebo treatment. rescue medications are allowed in both groups. eligibility criteria. peripheral neuropathic pain with pain intensity of at least 40 mm on a visual analog scale. outcomes. primary outcome is the intensity of pain on a visual analog scale after 4 weeks of treatment. secondary outcomes: intensity of pain after iv treatment; neurophysiologic measures (thermal thresholds, riii reflex); association of response to iv treatment with oral treatment efficacy.

Eligibility criteria:
inclusion criteria: * peripheral neuropathic pain * signed written informed consent exclusion criteria: * central neuropathic pain * current or past hepatic disease

Keywords: neuralgia valproate anticonvulsant drugs pain measurement randomized controlled trials
a pilot study to evaluate the efficacy of response guided therapy of peginterferon alfa plus ribavirin in the treatment of patients with hcv/hbv co-infection

Conditions: HBV/HCV Co-infection

Summary: this is an open label, randomized-controlled, comparative trial. hbv and hcv dually infected patients with negative hepatitis b e antigen (hbeag) were enrolled in the study. the definition of hbv and hcv dual infection included seropositivity of hcv antibody (anti-hcv) and hbsag for more than 6 months, together with positive serum hcv rna. eligible subjects were randomized into 2 groups at treatment initiation. subjects who were randomized into the genotype guided therapy (ggt) group received peg-ifn and standard dose rbv (1200 mg/day) for 48 weeks in subjects infected with hcv genotype 1 or peg-ifn and low dose rbv (800 mg/day) for 24 weeks in subjects infected with hcv genotype 2/3; the patients were then followed for 6 months. for subjects who were randomized into the response guided therapy (rgt) group, the duration of peg-ifn and rbv therapy was abbreviated to 24 weeks in subjects with hcv genotype 1, a pre-treatment low viral load (lvl, \< 400000 iu/ml) and rvr (defined ashcv rna \<50 iu/ml at 4th week of therapy); the duration was 16 weeks in subjects with hcv genotype 2/3 and rvr.


Eligibility criteria:
inclusion criteria: * seropositivity of hcv antibody (anti-hcv) and hbsag for more than 6 months, together with positive serum hcv rna. * negative hbeag * serum alanine aminotransferase (alt) levels between 1-10-fold of the upper limit of normal (uln) * treatment naive or had previously failed interferon monotherapy. exclusion criteria: * decompensated liver disease (child-pugh score ≥ 7) * pregnant or breast-feeding women * serum creatinine ≥ 2 mg/dl * evidence of alcoholism or drug abuse * any other known disease that was not suitable for peg-ifn therapy.
the active (use of the assurant® cobalt iliac stent system in the treatment of iliac vessel disease) study

Conditions: Peripheral Vascular Disease

Summary: the objective of this study is to evaluate the safety and efficacy of the assurant cobalt iliac stent system in the treatment of de novo and restenotic lesions in iliac arteries of subjects with peripheral artery disease (pad).

this study is being conducted to collect 9 month safety and efficacy data on the assurant cobalt iliac stent for all subjects enrolled into the study.

Eligibility criteria:
inclusion criteria: * the lesion(s) is either de novo or restenotic in nature, located in the common iliac artery and/or the external iliac artery; * the subject is symptomatic (fontaine stage ii or iii) with a target lesion stenosis ≥ 50% . * the target vessel(s) reference diameter is ≥ 6 mm and ≤ 10 mm by visual estimate; * the lesion length is \< 100 mm (10 cm) exclusion criteria: * excessive peripheral vascular disease(pvd), unresolved fresh thrombus or tortuousity,or heavily calcified. * tissue loss in the target extremities. * the target lesion is in a prosthetic vascular bypass graft or within 1 cm of a graft anastomosis; * the target lesion is in an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion. * the lesion requires treatment other than percutaneous transluminal angioplasty (pta) prior to stent placement; * other lesions requiring treatment or surgery within 30 days of the procedure (pre or post) with the exception of the non-target lesion(s). * inadequate distal run-off. * history of bleeding diatheses or coagulopathy or will refuse blood transfusions; * creatinine \> 2.5 mg/dl * platelet count \ 700,000 cells/mm3, or a white blood cell (wbc) of \<3,000 cells/mm3 * participation in another investigational device or drug study and has not completed the primary endpoint(s) or that clinically interferes with the study endpoints; * previously enrolled in the study.
clinical and urodynamic assessment of bladder sensation in multiple sclerosis

Conditions: Overactive Bladder

Summary: the aim of the study is to assess the association between bladder sensations progression during bladder filling and severity of overactive bladder (oab) in patients with multiple sclerosis.

lower urinary tract symptoms (luts) are frequent in central nervous system disorders especially in patients with multiple sclerosis (pwms). prevalence of luts is important (32 to 96.8%) and increases with multiple sclerosis (ms) duration and the severity of the neurological deficiencies and disabilities. overactive bladder (oab) with urgency, frequency, urgency urinary incontinence, is the most common symptom, reported by 37-99% of the pwms. voiding difficulties are less common, from 6 to 49%, and usually appear later with the course of the disease. urodynamics is a useful test recommended to understand the mechanism of bladder dysfunction, and look for risk factors of upper tract damage. detrusor overactivity is the most reported mechanism of overactive bladder, and describes the occurrence of uninhibited contractions of the detrusor during bladder filling. but abnormal bladder sensations, with increased or decreased sensations, have also been described. the prevalence of these abnormalities is not well described, however, in the absence of detrusor overactivity, abnormal afferent information (i.e., abnormal bladder sensations) is the plausible mechanism involved in urinary disorders. the assessment of bladder sensations is still a poorly explored field. bladder diary can be used for the collection of the intensity of need to void with a likert scale or numerical scale. during cystometry, it is recommended to collect different bladder sensations: first sensation of filling, first desire to void, strong desire to void, urgent desire to void. however, it has been described that bladder sensations progress in 8 to 9 different levels of intensity in healthy subjects. the aim of the study is to assess the association between bladder sensations progression during bladder filling and severity of oab in patients with multiple sclerosis.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * ms according to the 2017 mac donald diagnostic criteria * bladder disorders supposedly related to ms * indication to perform urodynamics * no current medication for bladder disorders * able to understand and right in french * affiliated to the "securite sociale" or "couverture medicale universelle (cmu)", or equivalent organism. exclusion criteria: * legal protection * pregnancy or breastfeeding mother * ms relapse during the past month * other associated neurological disease * genuine stress incontinence related to postpartum * treatment with antimuscarinics, alpha blockers, beta3 adrenergic, or tibial nerve stimulation in the past 15 days, or with botulinic toxin injection in the past 6 months * previous lower urinary tract surgery * inability to use the analogic device due to motor, sensory or ataxic disabilities

Keywords: overactive bladder multiple sclerosis bladder sensations
postoperative results of surgical treatment of lung cancer after 30 days

Conditions: Lung Neoplasms

Summary: this is a retrospective, descriptive analysis of (1) 30 day postoperative results of surgery for lung cancer, (2) 30 day outcome predictors - compared to an earlier similar study in the same hospital (st olav university hospital, trondheim, norway).


Eligibility criteria:
inclusion criteria: * lung cancer patients after surgery in 2002-2004 at dept for heart and lung surgery, st.olavs university hospital, trondheim, norway. exclusion criteria: * carcinoid tumor, small-cell lung cancer, lung metastases
postoperative pain after ultrasonically and laser-activated irrigation during root canal treatment

Conditions: Post-operative Pain

Summary: the aim of this prospective, randomized clinical study is to compare the frequency and intensity of post-operative pain after root canal treatment with ultrasonically-activated or laser-activated irrigation.

patients older than 18 years who require root canal treatment of an asymptomatic tooth with vital or necrotic pulp are included. those teeth are subjected to root canal treatment using hand and rotating/reciprocating instruments, in combination with irrigation (3% naocl, 17% edta). after chemomechanical preparation, the teeth are randomly allocated to one of the following groups, according to the final irrigant activation: * ultrasonically activated irrigation (uai), with an irrisafe file (satelec acteon, mérignac, france) held 1-3mm from working length, driven by an ultrasonic device, activated for 3 x 20 seconds. in between each 20-second cycle, each canal is rinsed with 1 ml naocl and finally with 2 ml. * laser-activated irrigation (lai), with the tip of a pulsed er:yag laser (2940 nm, fidelis ii, fotona) held above the canal entrance, activated for 2 x 30s. settings are 20 hz, 50 μs, 20 mj. in between each 30-second cycle, each canal is rinsed with 1 ml naocl and finally with 2 ml. the canals are then dried using paper points and obturated with gutta percha and an epoxy resin sealer using warm vertical condensation. finally, the endodontic access is sealed with a provisional or permanent filling. the patient is asked to keep a pain diary after the treatment, indicating postoperative pain on a visual analogue scale at 6, 24, 48 and 72 hours after treatment. pain medication (ibuprofen 400mg) is prescribed, and the intake of analgesic tablet is recorded at the same times. pre-treatment procedure * medical + dental history * clinical examination: sensibility tests, percussion, palpation, mobility, pockets measurement * radiographic examination * pulpal and periapical diagnosis * intensity of pre-op pain on 100mm vas scale * patient information and informed consent * explanation on how to complete the pain diary and how and when to return it endodontic protocol * anesthesia * rubber dam, disinfection of operative field * removal of caries and/or defective restorations * access cavity * build-up to provide a reservoir for the irrigation if necessary * crown-down preparation * length determination * apical enlargement irrigation protocol * 3% naocl * 17% edta when shaping completed * irrigation throughout the whole procedure with 27g notched-end needle 2 - 3 mm from wl

Eligibility criteria:
inclusion criteria: * subject has an asymptomatic (vas 0-0,4mm) tooth requiring primary endodontic treatment * subject must be able to undergo primary endodontic treatment exclusion criteria: * analgesic intake over the last 12h * immunocompromised patients * pregnant women * tooth with incompletely formed apex/apices * subjects with more than one tooth in need of rct * previously root canal treated teeth * subjects with intolerance on nsaid's

Keywords: root canal treatment root canal irrigation